| 2020-GHOS-69088 | |
| Researchers at Purdue University have developed potent inhibitors for the SARS-CoV-2 protease enzyme 3CLpro. Covid-19, an infection caused by the SARS-CoV-2 virus, has led to an ongoing global pandemic. Currently, no effective drug treatment is available for Covid-19. To find a potential therapeutic for Covid-19, Purdue researchers discovered a series of novel noncovalent functionalized bis-amide derivatives that were previously reported to inhibit a SARS-CoV-2 enzyme, 3CLpro. These are modified versions of previous compounds to improve drug-like characteristics and antiviral properties against SARS-CoV-2. The inhibitors have been evaluated in immunocytochemical and cellular assays against Covid-19 infections. These compounds show promise to be an effective treatment for Covid-19 upon further evaluation on in vivo systems. Advantages: -Potent Covid-19 Antiviral Properties -Improved Drug-Like Features Potential Applications: -Covid-19 Treatment -Pandemic Control -Pharmaceutical Research and Development Technology Validation: The bis-amide compounds potently inhibited SARS-CoV-2 in in vitro studies and immunocytochemistry assays. |
|
|
|
|
Mar 15, 2021
PCT-Gov. Funding
WO
(None)
(None)
Dec 1, 2020
Provisional-Gov. Funding
United States
(None)
(None)
May 15, 2020
Provisional-Gov. Funding
United States
(None)
(None)
|
|
|
Purdue Office of Technology Commercialization The Convergence Center 101 Foundry Drive, Suite 2500 West Lafayette, IN 47906 Phone: (765) 588-3475 Fax: (765) 463-3486 Email: otcip@prf.org |